TipRanks
Advertisement
Advertisement

DE:8AP Stock Latest News

Agios Pharmaceuticals price target raised to $50 from $46 at BofA
The FlyAgios Pharmaceuticals price target raised to $50 from $46 at BofA
12d ago
AGIO
Agios Pharmaceuticals Signals Momentum Amid Ongoing Losses
PremiumCompany Announcements
Agios Pharmaceuticals Signals Momentum Amid Ongoing Losses
2M ago
AGIO
Agios Pharmaceuticals price target raised to $52 from $46 at Citi
PremiumThe Fly
Agios Pharmaceuticals price target raised to $52 from $46 at Citi
2M ago
AGIO
Agios: Buy Rating Reiterated on Strong AQVESME Uptake and Pipeline Progress, Price Target Maintained at $46
PremiumRatings
Agios: Buy Rating Reiterated on Strong AQVESME Uptake and Pipeline Progress, Price Target Maintained at $46
2M ago
AGIO
Agios: Strong Mitapivat Launch and Growing Patient Uptake Drive Confident Buy Rating
PremiumRatings
Agios: Strong Mitapivat Launch and Growing Patient Uptake Drive Confident Buy Rating
2M ago
AGIO
Agios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright
PremiumThe FlyAgios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright
2M ago
AGIO
Agios Pharmaceuticals reports Q2 EPS ($1.69), consensus ($1.66)
Premium
The Fly
Agios Pharmaceuticals reports Q2 EPS ($1.69), consensus ($1.66)
2M ago
AGIO
AGIO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
AGIO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
AGIO
Agios Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $46 Price Target on Mitapivat Sickle Cell Catalyst and AQVESME Thalassemia Launch Momentum
PremiumRatings
Agios Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $46 Price Target on Mitapivat Sickle Cell Catalyst and AQVESME Thalassemia Launch Momentum
2M ago
AGIO
Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright
PremiumThe Fly
Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright
2M ago
AGIO
Morning Movers: Equifax sinks following second quarter earnings
PremiumThe Fly
Morning Movers: Equifax sinks following second quarter earnings
2M ago
GM
DHI
Agios Pharmaceuticals down 13% at $34.75 on topline results from tebapivat trial
PremiumThe Fly
Agios Pharmaceuticals down 13% at $34.75 on topline results from tebapivat trial
2M ago
AGIO
Agios Pharmaceuticals announces topline results from tebapivat trial
PremiumThe FlyAgios Pharmaceuticals announces topline results from tebapivat trial
2M ago
AGIO
Agios Pharmaceuticals rises 13.5%
Premium
The Fly
Agios Pharmaceuticals rises 13.5%
3M ago
AGIO
Mitapivat’s Priority Review in Sickle Cell Disease Supports First-in-Class 2026 Launch, Long-Term Growth; Buy Rating and $54 Price Target Maintained
Premium
Ratings
Mitapivat’s Priority Review in Sickle Cell Disease Supports First-in-Class 2026 Launch, Long-Term Growth; Buy Rating and $54 Price Target Maintained
3M ago
AGIO
Leerink sees Priority Review designation as positive sign for Agios’ mitapivat
PremiumThe Fly
Leerink sees Priority Review designation as positive sign for Agios’ mitapivat
3M ago
AGIO
H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat
PremiumThe Fly
H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat
3M ago
AGIO
Agios Pharmaceuticals rises 12.9%
PremiumThe Fly
Agios Pharmaceuticals rises 12.9%
3M ago
AGIO
Agios Pharmaceuticals price target raised to $46 from $40 at BofA
PremiumThe Fly
Agios Pharmaceuticals price target raised to $46 from $40 at BofA
3M ago
AGIO
Agios Pharmaceuticals price target raised to $41 from $36 at Truist
PremiumThe FlyAgios Pharmaceuticals price target raised to $41 from $36 at Truist
3M ago
AGIO
Agios Pharmaceuticals price target raised to $32 from $28 at RBC Capital
Premium
The Fly
Agios Pharmaceuticals price target raised to $32 from $28 at RBC Capital
3M ago
AGIO
Agios Pharmaceuticals granted priority review for mitapivat sNDA
Premium
The Fly
Agios Pharmaceuticals granted priority review for mitapivat sNDA
3M ago
AGIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >